| Autor: |
Phillips, T., Wang, M., Robak, T., Gallinson, D., Stevens, D., Patel, K., Ramadan, S., Wun, C., Jurczak, W., Smith, S. D. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p586-587, 2p |
| Abstrakt: |
Safety and Efficacy of Acalabrutinib, Bendamustine, and Rituximab in Patients with Treatment-Naive or Relapsed/Refractory Mantle Cell Lymphoma: Phase Ib Trial Grade 3-4 AEs occurred in 13 (72.2%) TN pts and 17 (85.0%) R/R pts, most commonly neutropenia ( I n i = 7, 38.9% [TN]; I n i = 10, 50.0% [R/R]). B Background: b Acalabrutinib (A) is a next-generation Bruton tyrosine kinase inhibitor approved for relapsed/refractory (R/R) mantle cell lymphoma (MCL). [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text